These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 30317986)
41. Inclisiran for the treatment of dyslipidemia. Nishikido T; Ray KK Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410 [TBL] [Abstract][Full Text] [Related]
42. PCSK9 and Hypercholesterolemia: Therapeutic Approach. Obradovic M; Zaric B; Sudar-Milovanovic E; Ilincic B; Stokic E; Perovic M; Isenovic ER Curr Drug Targets; 2018; 19(9):1058-1067. PubMed ID: 29210646 [TBL] [Abstract][Full Text] [Related]
43. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL; J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591 [TBL] [Abstract][Full Text] [Related]
44. Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events. Turgeon RD; Pearson GJ Am J Health Syst Pharm; 2018 Jun; 75(11):747-754. PubMed ID: 29802110 [TBL] [Abstract][Full Text] [Related]
45. [PCSK9 inhibitors : New treatment option in clinical practice]. Müller-Wieland D; Marx N Herz; 2016 Jun; 41(4):290-5. PubMed ID: 27215418 [TBL] [Abstract][Full Text] [Related]
47. PCSK9 Inhibition-Based Therapeutic Approaches: An Immunotherapy Perspective. Momtazi-Borojeni AA; Pirro M; Xu S; Sahebkar A Curr Med Chem; 2022; 29(6):980-999. PubMed ID: 34711156 [TBL] [Abstract][Full Text] [Related]
48. Hepatic HNF1 transcription factors control the induction of PCSK9 mediated by rosuvastatin in normolipidemic hamsters. Dong B; Singh AB; Shende VR; Liu J Int J Mol Med; 2017 Mar; 39(3):749-756. PubMed ID: 28204827 [TBL] [Abstract][Full Text] [Related]
49. Small molecules as inhibitors of PCSK9: Current status and future challenges. Xu S; Luo S; Zhu Z; Xu J Eur J Med Chem; 2019 Jan; 162():212-233. PubMed ID: 30448414 [TBL] [Abstract][Full Text] [Related]
51. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia. Tziomalos K Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622 [TBL] [Abstract][Full Text] [Related]
52. Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors. Panagiotopoulou O; Chiesa ST; Tousoulis D; Charakida M Curr Med Chem; 2020; 27(27):4494-4521. PubMed ID: 31453780 [TBL] [Abstract][Full Text] [Related]
53. PCSK9 and cancer: Rethinking the link. Mahboobnia K; Pirro M; Marini E; Grignani F; Bezsonov EE; Jamialahmadi T; Sahebkar A Biomed Pharmacother; 2021 Aug; 140():111758. PubMed ID: 34058443 [TBL] [Abstract][Full Text] [Related]
54. Novel treatment options for the management of heterozygous familial hypercholesterolemia. Polychronopoulos G; Tziomalos K Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604 [TBL] [Abstract][Full Text] [Related]
55. Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease. Cao G; Qian YW; Kowala MC; Konrad RJ Endocr Metab Immune Disord Drug Targets; 2008 Dec; 8(4):238-43. PubMed ID: 19075777 [TBL] [Abstract][Full Text] [Related]
56. Drugs for hypercholesterolaemia - from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition. Wierzbicki AS; Grant P Clin Med (Lond); 2016 Aug; 16(4):353-7. PubMed ID: 27481380 [TBL] [Abstract][Full Text] [Related]
60. Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives. Cho KH; Hong YJ Korean J Intern Med; 2020 Sep; 35(5):1045-1058. PubMed ID: 32921006 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]